|
Figure S4. Transgenic line Xla.Tg(Dre.gfap:EGFP)Larra. (A-C) Three different animals’ electroporated in the spinal cord with the CAG promoter driving the expression of EGFP in central canal cells. (D-F) Three different animals electroporated in the spinal cord with the zGFAP::EGFP construct driving specific expression in radial glial like cells in contact with the central canal. (G-J) Animals at different developmental stages of the transgenic line Xla.Tg(Dre.gfap:EGFP)Larra show in expression of EGFP in the neural tubeg at (G-G’) NF stage 23; (H-H′) NF stage 27; (I-I′) NF stage 31 and in the CNS at (J-J’) NF stage 41. (K-M) Double staining against (K) EGFP and (L) Sox2 in coronal section of the spinal cord at NF stage 43. Panels (M) showed merge image, and panels (M’, M”) are magnifications of the dorsal and ventral cells surrounding the central canal.
|
|
Figure S7. Transgenic line Xla.Tg(Dre.gfap:mCherry-Nitroreductase) allows selective cell ablation. (A) Diagram of injection and electroporation of the spinal cord at NF stage 50, indicating volume, concentration and parameters of electroporation. (B) Scheme of electroporation of the Dre.gfap:mCherry-Nitroreductase construct and treatment with vehicle or metronidazol (MTZ) at NF stage 50. (C-R) mCherry (red) expression in the spinal cord of animal electroporated at (C-D; I-J) 2 days post electroporation (dpe), before treatment; (E-F; K-L) 4 dpe and 2 days post treatment (dtt); (G-H; M-N) 7 dpe and 5 dtt, and (O- R) at 8 dpe and 6 dtt co-stained with Hoechst (blue). (S) The construct used to generate the transgenic line Xla.Tg(Dre.gfap:mCherry-Nitroreductase). (T, U) mCherry expression in the eye (arrow) and the brain of the transgenic animal at NF stage 42.
|
|
